<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> is used clinically for the prevention of <z:e sem="disease" ids="C0032962" disease_type="Disease or Syndrome" abbrv="">pregnancy complications</z:e> associated with prothrombotic disorders, especially <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies have suggested that <z:chebi fb="5" ids="28304">heparin</z:chebi> may exert direct effects on placental trophoblast, independently of its <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity </plain></SENT>
<SENT sid="2" pm="."><plain>We now demonstrate that <z:chebi fb="5" ids="28304">heparin</z:chebi> abrogates <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of primary first trimester villous trophoblast in response to treatment with the pro-inflammatory cytokines interferon (IFN)-gamma and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF)-alpha </plain></SENT>
<SENT sid="3" pm="."><plain>This multifunctional <z:chebi fb="0" ids="18085">glycosaminoglycan</z:chebi> also inhibited <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induced by other agents, including <z:chebi fb="0" ids="15738">staurosporin</z:chebi>, broad-spectrum kinase inhibitor and thrombin </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, <z:chebi fb="5" ids="28304">heparin</z:chebi> attenuated caspase-3 activity, a hallmark of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, in human first trimester villous and extravillous trophoblast cell lines treated with <z:chebi fb="0" ids="8005">peptidoglycan</z:chebi>, a Toll-like receptor-2 agonist isolated from Staphylococcus aureus </plain></SENT>
<SENT sid="5" pm="."><plain>The ability of <z:chebi fb="5" ids="28304">heparin</z:chebi> to antagonize cell <z:hpo ids='HP_0011420'>death</z:hpo> induced by such diverse apoptotic signals suggested that it acts as a survival factor for human trophoblast </plain></SENT>
<SENT sid="6" pm="."><plain>We demonstrate that <z:chebi fb="5" ids="28304">heparin</z:chebi>, like epidermal growth factor (EGF) and <z:chebi fb="5" ids="28304">heparin</z:chebi>-binding EGF (HB-EGF), elicits phosphorylation of the EGF receptor and activation of the <z:chebi fb="0" ids="26025">phosphatidyl</z:chebi> <z:chebi fb="1" ids="24848">inositol</z:chebi> 3-kinase (PI3K)-, the extracellular signal-related kinase 1/2 (ERK1/2)- and the c-Jun <z:chebi fb="0" ids="29318,29339">NH2</z:chebi> terminal kinase (JNK)-signal transduction pathways in primary villous trophoblast </plain></SENT>
<SENT sid="7" pm="."><plain>In summary, we have demonstrated that <z:chebi fb="5" ids="28304">heparin</z:chebi> activates multiple anti-apoptotic pathways in human trophoblast </plain></SENT>
<SENT sid="8" pm="."><plain>Our results suggest that <z:chebi fb="5" ids="28304">heparin</z:chebi> may be useful in the management of at-risk patients, even in the absence of an identifiable thrombophilic disorder </plain></SENT>
</text></document>